SILVER SPRING, Md.–InfraTrac, a product protection company with innovative anti-counterfeiting technology, announced the appointment of Dr. Harvey E. Bale, Jr., recently retired from the position of Director-General of the Geneva-based International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), to its Board of Advisors.

Dr. Bale is widely recognized as a leader in the fight against counterfeiting. As Director-General of IFPMA, he represented the research-based pharmaceutical industry and other manufacturers of prescription medicines, coordinating with the World Health Organization (WHO), the World Trade Organization (WTO) as well as other international organizations concerned with health and trade-related issues. As Director-General, he served as founding President of the Pharmaceutical Security Institute (PSI), an industry organization dedicated to combating counterfeiting. He was also a key collaborator in the establishment of the World Health Organization International Medical Products Anti-Counterfeiting Task Force (WHO IMPACT) and served as the first Chair of its Technology Subcommittee.

“Staying ahead of counterfeiters, while remaining cost-effective, presents a formidable brand protection challenge. Repackaging and the increasing sophistication of counterfeiters make clear that we cannot simply protect the package,” said Bale. “InfraTrac’s advanced, compact and highly mobile technology for protecting the product itself sets the company apart from others in this field, with the ability to protect generics and biologics as well.”

Dr. Bale has prior experience with the Pharmaceutical Research and Manufacturers of America as Senior Vice President for International Affairs, at Hewlett-Packard, and in the Office of the U.S. Trade Representative, in trade negotiations and in the Camp David negotiations on the settlement of Israeli/Palestinian issues. In 1986 he received the Distinguished Service Award from U.S. President Ronald Reagan, the highest award given to senior career government executives.

About InfraTrac

InfraTrac uses spectroscopy to detect and prevent counterfeiting of high value formulated and regulated substances including pharmaceuticals, chemicals and consumer products. InfraTrac’s platform includes counterfeit detection using a simple yes-no interface, and encryption software, which enables tagging of client substances, even at the batch level, using patent-pending covert NIR fingerprints. Easy-to-use field verification makes it possible to check throughout the supply chain.

For more information, please visit www.infratrac.com.